Wang Wanhua, Sun Guan, Zhang Luyuan, Shi Lei, Zeng Yanjun
Department of Neurosurgery and Neurology, The First People's Hospital of Kunshan, Jiangsu University, Suzhou, P. R. China.
Department of Neurosurgery, Fourth Affiliated Yancheng Hospital of Nantong University, Yancheng, P. R. China.
J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2607-2613. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.002. Epub 2014 Oct 5.
Many diseases include microRNAs (miRNAs) as reported biomarkers. The significance of circulating miRNAs for early diagnosis of acute stroke in humans is unknown. We aim to determine whether circulating miRNAs potentially serve as novel biomarkers for acute stroke.
We prospectively recruited patients with acute stroke and those with nonstroke disease. Patients with acute stroke were identified using magnetic resonance imaging (MRI) for early diagnosis. If the patient suffered from acute stroke that was detected with diffusion-weighted imaging, the patient was defined as an MRI(+) patient. Otherwise, it was defined as an MRI(-) patient. Circulating miRNAs were measured by miRNA microarray and real-time polymerase chain reaction (PCR) analysis.
A total of 136 patients were included in the study. Testing by miRNA microarray and real-time PCR analyses showed that hsa-miR-106b-5P and hsa-miR-4306 were present with markedly high abundance in patients of acute stroke, whereas hsa-miR-320e and hsa-miR-320d were present with quite low abundance in patients compared with healthy individuals. Compared with healthy individuals, the miRNAs were increased as in patients with acute stroke as follows: hsa-miR-106b-5P, 3.63-fold in MRI(-) patients and 23.90-fold in MRI(+) patients; hsa-miR-4306, 3.19-fold in MRI(-) patients and 5.30-fold in MRI(+) patients; hsa-miR-320e, .33-fold in MRI(-) patients and .13-fold in MRI(+) patients; and hsa-miR-320d, .23-fold in MRI(-) patients and .07-fold in MRI(+) patients.
Elevated hsa-miR-106b-5P and hsa-miR-4306 and decreased hsa-miR-320e and hsa-miR-320d in plasma may be novel biomarkers for the early detection of acute stroke in humans.
许多疾病都有报道称包含微小RNA（miRNA）作为生物标志物。循环miRNA对人类急性中风早期诊断的意义尚不清楚。我们旨在确定循环miRNA是否有可能作为急性中风的新型生物标志物。
我们前瞻性地招募了急性中风患者和非中风疾病患者。使用磁共振成像（MRI）对急性中风患者进行早期诊断。如果患者通过弥散加权成像检测出患有急性中风，则该患者被定义为MRI（+）患者。否则，定义为MRI（-）患者。通过miRNA微阵列和实时聚合酶链反应（PCR）分析测量循环miRNA。
本研究共纳入136例患者。通过miRNA微阵列和实时PCR分析检测发现，hsa-miR-106b-5P和hsa-miR-4306在急性中风患者中显著高丰度存在，而与健康个体相比，hsa-miR-320e和hsa-miR-320d在患者中的丰度相当低。与健康个体相比，急性中风患者中miRNA的增加情况如下：hsa-miR-106b-5P，MRI（-）患者中为3.63倍，MRI（+）患者中为23.90倍；hsa-miR-4306，MRI（-）患者中为3.19倍，MRI（+）患者中为5.30倍；hsa-miR-320e，MRI（-）患者中为0.33倍，MRI（+）患者中为0.13倍；hsa-miR-320d，MRI（-）患者中为0.23倍，MRI（+）患者中为0.07倍。
血浆中hsa-miR-106b-5P和hsa-miR-4306升高以及hsa-miR-320e和hsa-miR-320d降低可能是人类急性中风早期检测的新型生物标志物。
